GAMA
JUNO

Graticule Asia Macro Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

Graticule Asia Macro Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-100,000
Closed -$4.07M – 208
2015
Q3 		$4.07M Buy
+100,000
New +$4.39M 0.47% 39

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Graticule Asia Macro Advisors's JUNO Position: Q2 2017 in Review

Graticule Asia Macro Advisors sold out of Juno Therapeutics, Inc. (JUNO) in Q2 2017, closing a stake of 40,950 shares — an estimated $909K sold.

Graticule Asia Macro Advisors first reported a position in JUNO in Q2 2015 and held it in 6 quarters. The position peaked at $17.7M in Q3 2015. 173 funds tracked by Wall St. Rank hold JUNO as of Q2 2017.

  • Graticule Asia Macro Advisors reported no remaining Juno Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Graticule Asia Macro Advisors sold 40,950 Juno Therapeutics, Inc. shares in Q2 2017, an estimated $909K.
  • Graticule Asia Macro Advisors first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 6 quarters.
  • Graticule Asia Macro Advisors's Juno Therapeutics, Inc. position peaked at $17.7M in Q3 2015.
  • 173 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q2 2017.

Based on Graticule Asia Macro Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.